GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Akers Biosciences Inc (NAS:AKER) » Definitions » Asset Turnover

Akers Biosciences (Akers Biosciences) Asset Turnover : 0.00 (As of Dec. 2020)


View and export this data going back to 2014. Start your Free Trial

What is Akers Biosciences Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Akers Biosciences's Revenue for the three months ended in Dec. 2020 was $0.00 Mil. Akers Biosciences's Total Assets for the quarter that ended in Dec. 2020 was $30.28 Mil. Therefore, Akers Biosciences's Asset Turnover for the quarter that ended in Dec. 2020 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Akers Biosciences's annualized ROE % for the quarter that ended in Dec. 2020 was -47.17%. It is also linked to ROA % through Du Pont Formula. Akers Biosciences's annualized ROA % for the quarter that ended in Dec. 2020 was -43.42%.


Akers Biosciences Asset Turnover Historical Data

The historical data trend for Akers Biosciences's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akers Biosciences Asset Turnover Chart

Akers Biosciences Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.44 0.47 0.19 - -

Akers Biosciences Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.04 - - -

Competitive Comparison of Akers Biosciences's Asset Turnover

For the Medical Instruments & Supplies subindustry, Akers Biosciences's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akers Biosciences's Asset Turnover Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Akers Biosciences's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Akers Biosciences's Asset Turnover falls into.



Akers Biosciences Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Akers Biosciences's Asset Turnover for the fiscal year that ended in Dec. 2020 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2020 )/( (Total Assets (A: Dec. 2019 )+Total Assets (A: Dec. 2020 ))/ count )
=0/( (10.885+36.843)/ 2 )
=0/23.864
=0.00

Akers Biosciences's Asset Turnover for the quarter that ended in Dec. 2020 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2020 )/( (Total Assets (Q: Sep. 2020 )+Total Assets (Q: Dec. 2020 ))/ count )
=0/( (23.725+36.843)/ 2 )
=0/30.284
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Akers Biosciences  (NAS:AKER) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Akers Biosciences's annulized ROE % for the quarter that ended in Dec. 2020 is

ROE %**(Q: Dec. 2020 )
=Net Income/Total Stockholders Equity
=-13.148/27.874
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-13.148 / 0)*(0 / 30.284)*(30.284/ 27.874)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.0865
=ROA %*Equity Multiplier
=-43.42 %*1.0865
=-47.17 %

Note: The Net Income data used here is four times the quarterly (Dec. 2020) net income data. The Revenue data used here is four times the quarterly (Dec. 2020) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Akers Biosciences's annulized ROA % for the quarter that ended in Dec. 2020 is

ROA %(Q: Dec. 2020 )
=Net Income/Total Assets
=-13.148/30.284
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-13.148 / 0)*(0 / 30.284)
=Net Margin %*Asset Turnover
= %*0
=-43.42 %

Note: The Net Income data used here is four times the quarterly (Dec. 2020) net income data. The Revenue data used here is four times the quarterly (Dec. 2020) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Akers Biosciences Asset Turnover Related Terms

Thank you for viewing the detailed overview of Akers Biosciences's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Akers Biosciences (Akers Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036
Akers Biosciences Inc is engaged in developing, manufacturing and supplying rapid, point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician in a time- and cost-efficient manner. The pipeline products of the company focus on delivering diagnostic assistance in a variety of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious disease detection. The majority of the company's revenue comes from the United States.
Executives
Billy Joe White director 191 OTTO ST., PORT TOWNSEND WA 98368
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Christopher C Schreiber director, officer: Exec. Chairman and President AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086
Robert C Schroeder director 37 MAIN STREET, COLD SPRING HARBOR, NEW YORK NY 11724
Stuart M Benson officer: Chief Financial Officer EMPIRE STATE BUILDING, 350 5TH AVE., SUITE 7520, NEW YORK NY 10118
Hudson Bay Capital Management Lp 10 percent owner 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Sander Gerber 10 percent owner C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Howard Yeaton officer: CEO, CFO 79 LLOYD ROAD, HOHOKUS NJ 07423
John J Gormally director, officer: Chief Executive Officer 80 WALSH DRIVE, MAHWAH NJ 07430
Gary M Rauch officer: VP - Finance, Treasurer 842 ST REGIS COURT, WEST DEPTFORD NJ 08051
Tarbox Richard C Iii director AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086
Brandon Thomas Knox director 771 EAGLE ROAD, VILLANOVA PA 19085
Akers Raymond Francis Jr director, officer: Executive Chairman, Secretary 171 E. ESSEX AVE, SEWELL NJ 08080
Thomas J Knox director 1717 ARCH STREET, SUITE 3820, PHILADELPHIA PA 19103
Robert E Andrews director 215 4TH AVENUE, HADDON HEIGHTS NJ 08035